Who are G1 Therapeutics's investors?

G1 Therapeutics's investors include Lumira Ventures, Mountain Group Capital, RA Capital, Solasta Ventures, Hatteras Venture Partners.

How much funding has G1 Therapeutics raised?

G1 Therapeutics has disclosed $79.1M raised across 3 rounds.

Where is G1 Therapeutics headquartered?

G1 Therapeutics is headquartered in Research Triangle Park, US.

G1 Therapeutics

Research Triangle Park, US · Delaware corporation · 5 known investors

G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

Biotech

Founders & leadership

Mark A. VellecainExecutiveVenture Partner at Hatteras Venture Partners

Timothy SullivanNamed on SEC filing

Gregory MossinghoffNamed on SEC filing

Seth RudnickNamed on SEC filing

Ron LauferNamed on SEC filing

Michael GutchNamed on SEC filing

Thomas K LaundonNamed on SEC filing

Carol WebbNamed on SEC filing

Jay StrumNamed on SEC filing

Norman SharplessNamed on SEC filing

Board

Peter Kolchinsky in 𝕏Board directorManaging Partner at RA Capital

Frederic N. EshelmanBoard director

Investors · 5

Lumira VenturesToronto · $1M – $10M

Mountain Group CapitalNashville

RA CapitalBostonvia Peter Kolchinsky · board

Solasta VenturesBoston

Hatteras Venture Partnersreported · 2 sourcesResearch Triangle · $500K – $4Mvia Clay Thorp · board

Reported raises · per SEC filings

Form D private placements

$79.1M disclosed across 3 rounds · 2013–2016

▶$50MraisedJul 2016 · 21 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Timothy SullivanDirector
Peter KolchinskyDirector
Mark A. VellecaExecutive Officer, Director
Glenn MuirDirector
Gregory MossinghoffExecutive Officer
Seth RudnickDirector
Ron LauferDirector
Frederic N. EshelmanDirector
Christy ShafferDirector

Offering amount: $50M
Amount sold: $50M
First sale: Apr 2016
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$16.5MraisedFeb 2015 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ron LauferDirector
Christy ShafferDirector
Seth RudnickDirector
Carol WebbDirector
Clay ThorpDirector
Michael GutchDirector
Mark A. VellecaExecutive Officer, Director
Norman SharplessDirector
Gregory MossinghoffExecutive Officer

Offering amount: $33M
Amount sold: $16.5M
First sale: Feb 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$12.6MraisedJun 2014 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ron LauferDirector
Michael GutchDirector
Thomas K LaundonExecutive Officer
Carol WebbDirector
Jay StrumExecutive Officer
Christy ShafferDirector
Mark A. VellecaExecutive Officer, Director
Norman SharplessDirector
Seth RudnickDirector

Offering amount: $12.6M
Amount sold: $12.6M
First sale: Oct 2013
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does G1 Therapeutics do?: G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
Who are G1 Therapeutics's investors?: G1 Therapeutics's investors include Lumira Ventures, Mountain Group Capital, RA Capital, Solasta Ventures, Hatteras Venture Partners.
How much funding has G1 Therapeutics raised?: G1 Therapeutics has disclosed $79.1M raised across 3 rounds.
Where is G1 Therapeutics headquartered?: G1 Therapeutics is headquartered in Research Triangle Park, US.